Guidance and Standards for Breast Cancer Care in Europe

Abstract The increasing incidence and mortality rates of breast cancer have led to the necessity of initiating and developing clinical practice guidelines in order to optimize cancer control and provide patients with the best care. These guidelines are either national or issued by reputed relevant European societies—like European Society for Medical Oncology. Many of the recommendations are concordant in-between the guidelines. However, there are still considerable discrepancies to be noted between guidelines from different European countries, which could hinder physicians from implementing their recommendations. The present paper summarizes and compares the recommendations included in the various European guidelines.

Download Full-text

Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009

Thoracic Cancer ◽

10.1111/j.1759-7714.2010.00016.x ◽

2010 ◽

Vol 1 (2) ◽

pp. 83-86 ◽

Cited By ~ 6

Author(s):

Yan Xu ◽

Hongyu Liu ◽

Jun Chen ◽

Qinghua Zhou

Keyword(s):

Lung Cancer ◽

Clinical Practice ◽

Clinical Practice Guidelines ◽

Practice Guidelines ◽

European Society ◽

Medical Oncology ◽

Small Cell ◽

Small Cell Lung ◽

Cancer Network ◽

Original Edition

Download Full-text

Is breast cancer care in accord with clinical practice guidelines: a consumer audit

The Breast ◽

10.1054/brst.2002.0478 ◽

2002 ◽

Vol 11 (6) ◽

pp. 509-515 ◽

Cited By ~ 10

Author(s):

Philippa Williams ◽

Sally Redman ◽

Nicole Rankin ◽

Cindy Davis ◽

Bruce Armstrong ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Practice ◽

Clinical Practice Guidelines ◽

Practice Guidelines ◽

Cancer Care ◽

Breast Cancer Care

Download Full-text

Critical appraisal of the Minimal Clinical Recommendations (MCR) of the European Society for Medical Oncology (ESMO): challenges for a European framework for the development of clinical practice guidelines

Annals of Oncology ◽

10.1093/annonc/mdf246 ◽

2002 ◽

Vol 13 (9) ◽

pp. 1507-1508 ◽

Cited By ~ 4

Author(s):

B. Fervers ◽

T. Philip ◽

G.P. Browman

Keyword(s):

Clinical Practice ◽

Clinical Practice Guidelines ◽

Practice Guidelines ◽

European Society ◽

Critical Appraisal ◽

Medical Oncology ◽

Clinical Recommendations

Download Full-text

Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guidelines

Journal of Clinical Oncology ◽

10.1200/jco.2014.58.1322 ◽

2015 ◽

Vol 33 (2) ◽

pp. 209-217 ◽

Cited By ~ 171

Author(s):

Elena M. Stoffel ◽

Pamela B. Mangu ◽

Stephen B. Gruber ◽

Stanley R. Hamilton ◽

Matthew F. Kalady ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Practice ◽

Practice Guidelines ◽

Clinical Practice Guideline ◽

European Society ◽

Medical Oncology ◽

Familial Risk ◽

Hereditary Colorectal Cancer ◽

American Society ◽

Cancer Syndromes

Purpose To provide recommendations on prevention, screening, genetics, treatment, and management for people at risk for hereditary colorectal cancer (CRC) syndromes. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The Familial Risk–Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guideline published in 2013 on behalf of the European Society for Medical Oncology (ESMO) Guidelines Working Group in Annals of Oncology was reviewed for developmental rigor by methodologists, with content and recommendations reviewed by an ASCO endorsement panel. Results The ASCO endorsement panel determined that the recommendations of the ESMO guidelines are clear, thorough, and based on the most relevant scientific evidence. The ASCO panel endorsed the ESMO guidelines and added a few qualifying statements. Recommendations Approximately 5% to 6% of patient cases of CRC are associated with germline mutations that confer an inherited predisposition for cancer. The possibility of a hereditary cancer syndrome should be assessed for every patient at the time of CRC diagnosis. A diagnosis of Lynch syndrome, familial adenomatous polyposis, or another genetic syndrome can influence clinical management for patients with CRC and their family members. Screening for hereditary cancer syndromes in patients with CRC should include review of personal and family histories and testing of tumors for DNA mismatch repair deficiency and/or microsatellite instability. Formal genetic evaluation is recommended for individuals who meet defined criteria.

Download Full-text

Reply to the Letter to the Editor “Critical appraisal of the Minimal Clinical Recommendations (MCR) of the European Society for Medical Oncology (ESMO): challenges for a European framework for the development of clinical practice guidelines”,by B. Fervers, T. Philip andG. P. Browman (Ann Oncol 2002; 13: 1507–1509)

Annals of Oncology ◽

10.1093/annonc/mdf330 ◽

2002 ◽

Vol 13 (9) ◽

pp. 1509

Author(s):

R. Stahel

Keyword(s):

Clinical Practice ◽

Clinical Practice Guidelines ◽

Practice Guidelines ◽

European Society ◽

Critical Appraisal ◽

Medical Oncology ◽

Clinical Recommendations ◽

Letter To The Editor

Download Full-text

Breast Cancer in Europe: Epidemiology, Risk Factors, Policies and Strategies. A Literature Review

Global Journal of Health Science ◽

10.5539/gjhs.v10n11p1 ◽

2018 ◽

Vol 10 (11) ◽

pp. 1 ◽

Cited By ~ 1

Author(s):

Bashaier Abdullah Aljohar ◽

Mohammed Ahmedhani Kilani

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Literature Review ◽

Cancer Control ◽

Mortality Rates ◽

Current Status ◽

Public Health Issue ◽

The European Union ◽

Cancer Risk Factors ◽

Incidence And Mortality

INTRODUCTION: Breast cancer is the most commonly diagnosed cancer in European women, accounting for 28.8% of the total number of cancer diagnosis in Europe. Over the past few decades, several factors have led to remarkable improvements in overall breast cancer outcomes in Europe, such as early detection, screening, and progresses in treatment. However, breast cancer remains the most common cancer in females in Europe, yet more there is an increase in the incidence and mortality rates in some European countries. This research summarizes the current status of breast cancer in Europe, including epidemiology, risk factors, policies, and strategies. The results can help to better identify this health problem, which could help in developing better breast cancer control or prevention strategies and policies. METHODS: A literature review was conducted using five electronic databases (PubMed, Google Scholar, ProQuest, Eurostat, BioMed) and the European Commission reports for studies that reported on epidemiology and risk factors of breast cancer, or policies and strategies that target it in Europe. In addition, the Social Ecological Model (SEM) was used in categorizing the breast cancer risk factors into different levels. RESULTS: Europe and North America have the highest rate of breast cancer globally. Incidence and prevalence of breast cancer vary across Europe, and so does its mortality rates. Breast cancer was found to be associated with a number of risk factors, including but not limited to aging, use of hormone therapy, older age at the first birth, and smoking which are common in Europe. Cancer in general, and breast cancer have attracted specific attention, and the European Union has focused many of the resources and expertise on the topic. CONCLUSION & RECOMMENDATIONS: Breast cancer remains a major public health issue in Europe, despite the efforts and actions being taken. Therefore, current efforts against breast cancer in Europe need to be revisited and improved.

Download Full-text